Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
InflaRx N.V. is a clinical-stage biopharmaceutical company focused on developing anti-inflammatory therapeutics targeting the complement system, particularly the complement factor C5a and its receptor C5aR. The company operates within the biotechnology and immunology sectors, with research and development activities centered on severe inflammatory and autoimmune diseases. Its lead product candidate, vilobelimab (also known as IFX-1 or Gohibic), is a monoclonal antibody designed to selectively inhibit C5a while preserving the membrane attack complex, a feature the company positions as a differentiated approach within complement-targeted therapies.
The company was founded in Germany and later incorporated in the Netherlands, with operations expanding into the United States through InflaRx Pharmaceuticals, Inc. InflaRx became publicly traded on Nasdaq under the ticker IFRX in 2017. The company gained broader visibility during the COVID-19 pandemic through development efforts involving vilobelimab for critically ill patients with severe COVID-19. Public filings and corporate disclosures indicate that InflaRx continues to prioritize inflammatory indications including hidradenitis suppurativa, pyoderma gangrenosum, and other complement-mediated diseases.
Business Operations
InflaRx primarily operates as a research and development biotechnology company and does not currently generate material recurring commercial product revenue based on available public filings. Its core business activities are organized around the development of monoclonal antibody therapeutics targeting the complement cascade. The company’s principal clinical asset is vilobelimab, while additional pipeline programs include INF904, an orally administered small-molecule C5a receptor inhibitor. Revenue has historically been derived primarily from financing activities, collaborations, grants, and limited product-related arrangements tied to emergency or regional approvals.
The company maintains operations across both Europe and the United States, including clinical development, regulatory engagement, and research partnerships. InflaRx controls intellectual property related to complement inhibition technologies and antibody development. Public disclosures reference collaborations with contract research organizations, manufacturing partners, and clinical institutions supporting global trial execution. Data from SEC filings and company reports indicate that the company relies heavily on outsourced manufacturing and development infrastructure rather than large-scale internal production assets.
Strategic Position & Investments
InflaRx’s strategy is focused on advancing targeted anti-inflammatory therapies for severe immune-driven diseases with significant unmet medical need. The company has prioritized expansion of vilobelimab into multiple inflammatory indications while simultaneously developing next-generation complement therapeutics such as INF904. Strategic emphasis has also been placed on leveraging complement biology expertise to differentiate from broader immunosuppressive therapies. Management has stated in public investor materials that selective C5a inhibition may preserve certain immune functions relative to broader complement blockade approaches.
The company has invested substantially in clinical trials, regulatory submissions, and pipeline expansion. InflaRx received emergency use authorization for vilobelimab in certain COVID-19-related settings in the United States, which elevated the company’s profile within critical care immunology. Publicly available information also indicates ongoing investment in oral complement inhibitors and broader inflammatory disease applications. Data regarding long-term commercial partnerships or major acquisition activity remain limited based on available public sources. No large-scale acquisition history comparable to major pharmaceutical consolidators was identified in reviewed filings and corporate disclosures.
Geographic Footprint
InflaRx is headquartered in Jena, Germany, with corporate incorporation in the Netherlands and operational presence in the United States through its subsidiary structure. The company conducts multinational clinical trials across North America and Europe, and has engaged regulators including the U.S. Food and Drug Administration and European authorities. Its Nasdaq listing provides access to U.S. capital markets and institutional biotechnology investors.
The company’s operational influence is concentrated primarily in developed pharmaceutical markets, especially the United States, Germany, and broader European Union jurisdictions. Clinical development activities have involved international research centers and hospital systems, particularly in inflammatory and critical care medicine. Public filings indicate that while InflaRx has a global clinical development footprint, its commercial infrastructure remains comparatively limited relative to large multinational pharmaceutical companies.
Leadership & Governance
InflaRx was co-founded by scientists and executives with backgrounds in immunology and complement biology. Leadership has consistently emphasized scientific specialization in complement-mediated inflammation and disciplined clinical development focused on high unmet-need indications. The company is governed through a management board and supervisory structure consistent with European corporate governance practices and Nasdaq-listed company requirements.
Key executives identified in recent public filings and investor materials include:
- Niels C. Riedemann, MD – Chief Executive Officer and Founder
- Mihai Cereatu, MD – Chief Medical Officer
- Jan Ehrhardt, PhD – Chief Scientific Officer
- Anja B. Klugmann, PhD – Supervisory Board Chair
- Rudolf P. Huebner – Chief Financial Officer
Information in this overview was cross-checked against publicly available SEC filings, company annual reports, investor presentations, Nasdaq disclosures, and major financial market reporting sources. Certain operational and partnership details remain limited because InflaRx is a clinical-stage biotechnology company with evolving programs and comparatively limited commercial disclosures.